Impact BioMedical Inc (IBO) USD0.001

Sell:$0.40Buy:$0.42$0.03 (7.87%)

Prices delayed by at least 15 minutes
Sell:$0.40
Buy:$0.42
Change:$0.03 (7.87%)
Prices delayed by at least 15 minutes
Sell:$0.40
Buy:$0.42
Change:$0.03 (7.87%)
Prices delayed by at least 15 minutes

Company Information

About this company

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.

Key people

Frank D. Heuszel
Chairman of the Board, Chief Executive Officer
Todd D. Macko
Chief Financial Officer
Mark Suseck
Chief Operating Officer
Elise Brownell
Director
Heng Fai Chan
Director
Jason Grady
Director
Melissa Sims
Director
Castel B. Hibbert
Independent Director
Click to see more

Key facts

  • EPIC
    IBO
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US45259L2051
  • Market cap
    $5.28m
  • Employees
    2
  • Shares in issue
    12.09m
  • Exchange
    Nyse American LLC
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.